Table 1

Characteristics of the female chronic low back pain (CLBP) patients and female healthy controls (HC)
No. Age (years) Duration of pain (month) VASQST NRS4average NRS4max BDI RDQ Reported medications (as needed)
1 52 360 5.8 4 8 11 15 No medication at all
2 54 168 5.1 5 7 12 6 Diclofenac (5-10/month)
3 49 120 1.0 2 2 2 2 Ibuprofen (2-3/month)
4 52 88 3.0 3 3 9 5 Diclofenac (0-8/month)
5 49 240 2.2 5 8 4 5 Ibuprofen (0-1/month)
6 54 108 4.6 3 6 6 3 Diclofenac (2-3/month)
7 50 > 60 3.5 5 7 11 5 Flupirtin (1-10/month)
8 56 > 60 3.5 4 7 9 6 No medication at all
9 56 > 60 1.1 4 7 11 2 Diclofenac (0-10/month)
10 44 > 60 1.0 1 1 7 2 Ibuprofen (0-3/month)
11 55 147 3.6 3 5 4 5 No medication at all
12 54 > 60 3.1 5 6 7 3 Ibuprofen (0-10/month)
13 48 > 60 3.8 2 4 2 6 No medication at all
14 56 > 60 1.0 2 3 11 1 No medication at all
CLBP (mean ± SD) 52.1 ± 3.7 > 60** 3.0 ± 1.7** 3.4 ± 1.4** 5.3 ± 2.3** 7.6 ± 3.5** 4.7 ± 3.4**
HC (mean ± SD) 51.9 ± 4.9 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 1.8 ± 1.5 0.1 ± 0.5

VASQST, 100 mm visual analog scale (VAS): current pain intensity before Quantitative sensory testing (QST); NRS 4average, numerical rating scale (NRS) pain intensity rating in response: “How would you rate your average pain over the last four weeks?”; NRS 4max, numerical rating scale (NRS) pain intensity rating in response: “How would you rate your highest pain intensity experienced within the last four weeks?” VAS/NRS left anchor with 0 = “no pain” and right anchor with 100/10 = “pain as bad as you can imagine”; BDI – Beck Depression Inventory [28]; RDQ – Roland and Morris Disability Questionnaire [63–65]. Reported medications: Mean use of medication; however, all CLBP patients were without any analgesic medication for at least 48 hours before the examination. All participants were employed. Significant difference between CLBP and HC: ** - P < 0.001.

Puta et al.

Puta et al. BMC Neurology 2012 12:98   doi:10.1186/1471-2377-12-98

Open Data